Article info

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System

Authors

  1. Correspondence to Dr Robert Hoepner, Department of Neurology, Inselspital University Hospital Bern, Bern 3012, Switzerland; robert.hoepner{at}insel.ch
View Full Text

Citation

Pistor M, Hoepner AGF, Lin Y, et al
Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System

Publication history

  • Received April 29, 2021
  • Accepted July 4, 2021
  • First published July 20, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.